bimagrumab + semaglutide Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity Bimagrumab-Semaglutide Combination Achieves Significant Weight

Pills or injections

For clinicians and patients, this is a moment of transition

When evaluating the effects of treatment, if all people adhered to treatment1, people treatedwith CagriSema 2.4 mg/2.4 mg achieved a weight loss of 23.0% after 84 weeks compared to 25.5% with tirzepatide 15 mg

Semaglutide can lower blood sugar, raising concerns for people with hypoglycemia history

CONVENIENT SINGLE-SERVE PACKETS: 16oz sticks designed for more hydration in every servingjust mix one with water for fast, functional hydration anytime youre pushing your limits

As the use of GLP-1 receptor agonists continues to expand for the treatment of type 2 diabetes and obesity, questions have emerged about their potential gastrointestinal side effectsparticularly gastroesophageal reflux disease (GERD)